Advertisement

Document › Details
eTheRNA Immunotherapeutics N.V.. (2/3/22). "Press Release: eTheRNA Announces Research Agreement with Merck to Access mRNA technologies". Niel.
![]() |
Organisation | Etherna Immunotherapies N.V. |
Today | Etherna N.V. | |
Group | Etherna (Group) | |
Organisation 2 | Merck KGaA | |
Group | Merck (DE) (Group) | |
![]() |
Product | mRNA technology |
Product 2 | lipid nanoparticle technology (LNP technology) | |
![]() |
Index term | Merck (DE)–Etherna: mRNA technology, 202202– collab research using Etherna’s mRNA + LNP technologies to evaluate therapeutic feasibility |
![]() |
Person | Powell, Steven (eTheRNA CEO 202006 before Macrophage Pharma 201705 CEO) |
eTheRNA immunotherapies NV (“eTheRNA”) is pleased to announce the start of a strategic partnership with Merck with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA’s proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck.
The ongoing pandemic has underlined the capability for mRNA vaccines as a new therapeutic modality. eTheRNA and Merck both recognise the potential for using targeted mRNA therapeutics in an expanded range of diseases. With this collaboration, eTheRNA and Merck will assess the feasibility of using eTheRNA’s mRNA and LNP technologies to develop therapeutic vaccination approaches in models of disease. If successful, mRNAs encoding antigens nominated by Merck and directly relevant for human diseases will then be designed and evaluated preclinically.
Steven Powell, eTheRNA CEO stated “We are extremely pleased to sign this partnership agreement with Merck, a leading German science and technology company. As two companies committed to innovation and creating patient focused solutions, we are excited about the many advantages such a partnership can offer to improve patient care and address a significant market need”.
About eTheRNA immunotherapies
eTheRNA immunotherapies NV is developing immunotherapy and vaccine products for the treatment of cancer and infectious disease from its mRNA chemistry, antigen identification, lipid chemistry and delivery and process engineering platforms. The company is headquartered in Belgium and was established in 2013. Its founding shareholders include Progress Pharma and VUB. eTheRNA is supported by an international group of specialised investors; BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE. LTD, Grand Decade Development Limited, Fund+, LSP, Novalis Lifesciences, Omega Funds, PMV and Ying Zhou Enterprise Management Company Limited who share the Company’s ambition to build a world-leading company in the RNA field. To date, the Company has raised €63 million of venture funding. Further details relating to eTheRNA’s R&D pipeline can be found at https://www.etherna.be/immunotherapies-rd-pipeline/.
For more information, please contact:
eTheRNA immunotherapies
Johanna Madero
[email protected]
Record changed: 2023-06-05 |
Advertisement

More documents for Etherna (Group)
- [1] Etherna N.V.. (7/10/24). "Press Release: Antonin (Tony) de Fougerolles Appointed as New Chair of Etherna". Niel....
- [2] Etherna N.V.. (4/16/24). "Press Release: Shelly West Joins Etherna as Business Development Director US". Niel....
- [3] Etherna N.V.. (10/17/23). "Press Release: mRNA/LNP Technology Platform Company Etherna Names Bernard Sagaert as Chief Executive Officer and Marijn Dekkers as Chairman of the Board". Niel....
- [4] Etherna N.V.. (6/8/23). "Press Release: Steffen Helmling Joins Etherna as Chief Business Officer". Niel....
- [5] eTheRNA Immunotherapeutics N.V.. (8/23/22). "Press Release: mRNA Leading Expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers Investing EUR 39M Series B2 Financing in mRNA Technology Platform Company eTheRNA". Niel....
- [6] eTheRNA Immunotherapeutics N.V.. (8/3/21). "Press Release: eTheRNA Immunotherapies Opens Office in Hong Kong to Support and Build on Its Growing Activities in China and Broader Asia-Pacific". Niel....
- [7] eTheRNA Immunotherapeutics N.V.. (6/16/20). "Press Release: eTheRNA Raises EUR 34 Million in Series B Financing to Accelerate Multiple mRNA Therapeutic Development Programs Through to Clinical Proof of Concept". Niel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top